The PROACC-1 trial has already demonstrated that neutralizing GDF15 with ponsegromab leads to weight gain, increased appetite, and improved functional performance, underscoring the role of GDF15 as a central regulator of cancer-associated metabolic dysfunction [152]. Here, GDF15 is linked to cancer.